Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hematopoiesis01:21

Hematopoiesis

5.5K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.5K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.3K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

3.2K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structural variant discovery and diagnostic impact in rare diseases from short-read and long-read sequencing.

medRxiv : the preprint server for health sciences·2026
Same author

RAG-mediated structural variation and its impact on relapse risk in acute lymphoblastic leukemia.

medRxiv : the preprint server for health sciences·2026
Same author

Shifting IRES versus Cap-initiated translation during homeostatic stem cell differentiation and stress.

Science advances·2026
Same author

Epigenome editing of human hematopoietic stem cells enables sustained and reversible thrombosis prevention.

bioRxiv : the preprint server for biology·2026
Same author

Genetic influences on haematopoiesis.

Nature reviews. Genetics·2026
Same author

Modeling mitochondrial inheritance enables high-precision single-cell lineage tracing in humans.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Aug 9, 2025

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.3K

Hacking hematopoiesis - emerging tools for examining variant effects.

Michael Gundry1,2,3, Vijay G Sankaran1,2,3

  • 1Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Disease Models & Mechanisms
|February 24, 2023
PubMed
Summary
This summary is machine-generated.

Understanding blood cell production (hematopoiesis) is key. New genome editing tools help validate genetic links to blood disorders, overcoming previous research hurdles.

More Related Videos

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.7K
Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting
07:01

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting

Published on: May 2, 2025

259

Related Experiment Videos

Last Updated: Aug 9, 2025

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.3K
Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.7K
Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting
07:01

Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting

Published on: May 2, 2025

259

Area of Science:

  • Hematology
  • Genetics
  • Molecular Biology

Background:

  • Hematopoiesis is the continuous production of blood and immune cells, regulated by numerous gene products.
  • Human genetic variation studies, including monogenic blood disorders and large-scale cohorts, have revealed thousands of genomic loci linked to blood traits and diseases.

Purpose of the Study:

  • To discuss the challenge of functionally validating newly discovered genomic loci associated with blood cell traits and diseases.
  • To highlight emerging methods, particularly genome editing technologies, for high-throughput functional assessment of these loci.
  • To identify existing barriers in connecting genetic variants to their functions in hematopoiesis.

Main Methods:

  • Review of insights from studies on human genetic variation and monogenic blood disorders.
  • Analysis of findings from large-scale biobanks and cohorts identifying genomic loci associated with blood traits.
  • Discussion of recent innovations in genome editing for functional validation.
  • Examination of challenges in manipulating primary hematopoietic cell genomes.

Main Results:

  • Studies on human genetic variation have significantly advanced our understanding of hematopoiesis.
  • Thousands of genomic loci associated with blood cell traits and diseases have been identified, some modifying known blood disorders.
  • Most identified loci require functional validation, presenting a significant bottleneck.

Conclusions:

  • Genome editing innovations offer promising avenues for high-throughput functional assessment of genetic loci influencing hematopoiesis.
  • Overcoming challenges in primary hematopoietic cell genome manipulation is crucial for progress in connecting genetic variants to function.
  • Continued research is needed to bridge the gap between genetic discoveries and mechanistic understanding in blood cell development.